Director John Burgess receives 7,000 Taylor Devices (TAYD) stock options at $56.43
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
TAYLOR DEVICES, INC. director John Burgess received a grant of stock options on April 18, 2026. He was awarded options for 7,000 shares of common stock with an exercise price of $56.43 per share. After this compensation grant, he holds options for 7,000 shares directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Burgess John
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 7,000 | $0.00 | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 7,000 shares (Direct, null)
Footnotes (1)
Key Figures
Options granted: 7,000 shares
Exercise price: $56.43 per share
Grant date: April 18, 2026
+3 more
6 metrics
Options granted
7,000 shares
Stock option grant to director John Burgess
Exercise price
$56.43 per share
Conversion or exercise price of options
Grant date
April 18, 2026
Option grant and exercise date
Expiration date
April 18, 2036
Option expiration for 7,000-share grant
Total options after transaction
7,000 shares
Derivative holdings following reported grant
Transaction price per option
$0.00
Compensation grant, no cash paid for options
Key Terms
Stock Option (Right to Buy), transaction code "A", exercise price, Common Stock, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)""
transaction code "A" regulatory
"transaction_code_description: "Grant, award, or other acquisition""
exercise price financial
"conversion_or_exercise_price: "56.4300""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
Common Stock financial
"underlying_security_title: "Common Stock""
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
derivative financial
"transaction_type: "derivative""
A derivative is a financial contract whose value depends on the price or performance of another asset or measure — for example a stock, index, interest rate, commodity, or currency. Investors use derivatives like insurance or leveraged bets to hedge risk, speculate, or gain exposure without owning the underlying asset; they can protect portfolios but also amplify losses and introduce counterparty and market risk.
FAQ
What did John Burgess acquire in this TAYD Form 4 filing?
John Burgess received a grant of stock options for 7,000 shares of Taylor Devices common stock. These options give him the right to buy shares at a fixed price as part of his director compensation package.
What is the exercise price of the TAYD stock options granted to John Burgess?
The stock options granted to John Burgess have an exercise price of $56.43 per share. This is the price at which he can buy Taylor Devices common stock when he chooses to exercise the options.
How many Taylor Devices options does John Burgess hold after this grant?
After this grant, John Burgess holds options for 7,000 shares of Taylor Devices common stock. The Form 4 shows this as his total derivative holdings following the reported transaction.
Was the TAYD Form 4 transaction a market purchase or sale?
The Form 4 shows a grant/award acquisition of stock options, not an open-market trade. The transaction code "A" indicates the options were granted as compensation rather than bought or sold in the market.
What are the key dates for John Burgess’s TAYD stock options?
The options were granted on April 18, 2026 and are scheduled to expire on April 18, 2036. These dates define when the options begin and when the right to exercise them ends.